Loading...
Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction
BACKGROUND: Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits in using Group 1 PH therapies in these patients, particularly in seve...
Na minha lista:
| Udgivet i: | J Thorac Dis |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
AME Publishing Company
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8024797/ https://ncbi.nlm.nih.gov/pubmed/33841939 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd-20-1635 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|